Open access

172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM)
Colin Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Joshua Rios, Tarsem Moudgil, Bernard Fox, Nick Morris, B Bell, Andrew Weinberg

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A103; DOI: 10.1136/jitc-2020-SITC2020.0172
173 An in vivo CRISPR/Cas9 screening platform to identify T cell enhancing edits in distinct solid tumor microenvironments
Amy Becker, Troy Luster, Ishina Balwani, Nachiket Shevale, Jingwei Sun, Erica Del Aguila, Jeff Jones, Srijani Sridhar, Nishit Patel, Daniel O’Connell, Reynald Lescarbeau, Birgit Schultes

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A103-A104; DOI: 10.1136/jitc-2020-SITC2020.0173
175 A Fas-4–1BB immunomodulatory fusion protein converts a pro-death to a pro-survival signal, enhancing T cell function and efficacy of adoptive cell therapy in murine models of AML and pancreatic cancer
Shannon Oda, Kristin Anderson, Philip Greenberg, Nicolas Garcia, Pranali Ravikumar, Patrick Bonson, Cody Jenkins, Summer Zhuang, Andrew Daman, Shannon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A104-A105; DOI: 10.1136/jitc-2020-SITC2020.0175
176 Evaluating the safety of tumor treating fields (TTFields) application to the torso – in vivo studies
Shiri Davidi, Roni Blat, Mijal Munster, Anna Shteingauz, Shay Cahal, Moshe Giladi, Uri Weinberg, Yoram Palti, Moshe Giladi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A105; DOI: 10.1136/jitc-2020-SITC2020.0176
177 A severe cytokine release syndrome with respiratory failure in recurrent mesothelioma induced by EpCAM CAR-T cells infusion: a case report
Sitong Wang, Juemin Fang, Hui Wang, Qing Xu

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A105; DOI: 10.1136/jitc-2020-SITC2020.0177
179 Immunotherapy trials lack a biomarker for inclusion: implications for drug development
Jacob Adashek, Alexey Goloubev, Shumei Kato, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A106; DOI: 10.1136/jitc-2020-SITC2020.0179
181 Anlyasis of therapeutic effect and safty of PD-1 inhibitors in clinical treatment of oral and maxillofacial malignant tumors
Haochuan Liu, Yaqiong Jie, Xinguang Han

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108; DOI: 10.1136/jitc-2020-SITC2020.0181
183 Overcoming immunotherapy resistance in T cell-inflamed lung cancer
Brendan Horton, Brendan Horton, Duncan Morgan, Noor Momin, Vidit Bhandarkar, Dane Wittrup, Chris Love, Stefani Spranger

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A108-A109; DOI: 10.1136/jitc-2020-SITC2020.0183
21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients
Michal Harel, Coren Lahav, Eyal Jacob, Eran Issler, Haim Bar, Adam Dicker, Ofer Sharon, Antonietta Bacchiocchi, Ruth Halaban, Mario Sznol, Yuval Shaked

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A11-A12; DOI: 10.1136/jitc-2020-SITC2020.0021
189 A clear increase in TILs and modest tumor growth inhibition by pembrolizumab in prostate cancer tumors growing in bone of CD34+ engrafted NOG mice
Suominen Suominen, Justyna Zdrojewska, Jenni Mäki-Jouppila, Philip Dube, Ivan Gladwyn-Ng, Paul Volden, Jukka Rissanen, Mari Suominen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A111-A112; DOI: 10.1136/jitc-2020-SITC2020.0189

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages